Intestinal Research

Hui Won Jang

3 Articles

Accuracy of three different fecal calprotectin tests in the diagnosis of inflammatory bowel disease: Hui Won Jang, Hyun Sook Kim, Soo Jung Park, Sung Pil Hong, Tae Il Kim, Won Ho Kim, Jae Hee Cheon; Intest Res 2016;14(4):305-313. Published online October 17, 2016; DOI: https://doi.org/10.5217/ir.2016.14.4.305

<b>Background/Aims</b><br/>

Several studies have found that the measurement of fecal calprotectin is useful for the early diagnosis of inflammatory bowel disease (IBD). We compared the effectiveness of three different fecal calprotectin kits for initial diagnosis in patients with suspected IBD.

Methods

We enrolled 31 patients with IBD (18 Crohn's disease [CD], 11 ulcerative colitis [UC], and two intestinal Behçet's disease), five with irritable bowel syndrome (IBS), and five with other colitis (four infectious colitis and one intestinal tuberculosis). Diagnosis was based on clinical, laboratory, and endoscopic examinations. Fecal samples were obtained at the first diagnosis and calprotectin levels were measured using three different kits (Quantum Blue® Calprotectin, EliA™ Calprotectin, and RIDASCREEN® Calprotectin).

Results

The overall accuracy for differentiating IBD from IBS or other colitis was 94% and 91%, respectively, for Quantum Blue® (cutoff, 50 µg/g); 92% and 89%, respectively, for EliA™ (cutoff, 50 µg/g); and 82% and 76%, respectively, for RIDASCREEN® (cutoff, 50 µg/g). In patients with CD, the results of Quantum Blue® Calprotectin and EliA™ Calprotectin correlated significantly with levels of the Crohn's disease activity index (Spearman's rank correlation coefficient, r=0.66 and r=0.49, respectively). In patients with UC, the results of EliA™ Calprotectin correlated significantly with the Mayo score (r=0.70).

Conclusions

Fecal calprotectin measurement is useful for the identification of IBD. The overall accuracies of the three fecal calprotectin kits are comparable.

Citations

Citations to this article as recorded by

Network pharmacology analysis and animal experiment validation of inflammation inhibition by Swertiamarin in treating Ulcerative colitis
Tang Jiafeng, Wang Lijuan, Wei Lan, You Yiqing, Yang Shiyu, Zeng Tao, Dang Tingting, Sun Haoli, Li Xiaoshan, Zhang Yan
Naunyn-Schmiedeberg's Archives of Pharmacology.2025;[Epub] CrossRef
Values of serum intestinal fatty acid-binding protein, fecal calprotectin, and fecal human β-defensin 2 for predicting necrotizing enterocolitis
Sujia Liu, Yongle Liu, Shuhua Lai, Yingling Xie, Wenlong Xiu, Changyi Yang
BMC Pediatrics.2024;[Epub] CrossRef
Multimodal Ultrasound Technology Combined with Fecal Calprotectin Assessment in Clinical Studies of Inflammatory Bowel Disease
泊辛陈
Advances in Clinical Medicine.2024; 14(07): 1110. CrossRef
The role of platelet to lymphocyte ratio and neutrophil to lymphocyte ratio in ulcerative colitis
Yujin Jeong, Seong Ran Jeon, Hyun Gun Kim, Jung Rock Moon, Tae Hee Lee, Jae Young Jang, Jun-Hyung Cho, Jun Seok Park, Heesu Park, Ki-hun Lee, Jin-Oh Kim, Joon Seong Lee, Bong Min Ko, Suyeon Park
Intestinal Research.2021; 19(1): 62. CrossRef
The utility of faecal and urine biomarkers for small bowel diseases
M.S. Ismail, Serhiy Semenov, Deirdre McNamara
Current Opinion in Gastroenterology.2021; 37(3): 284. CrossRef
A comparison of diagnostic performance between two quantitative rapid fecal calprotectin assays in detecting active inflammatory bowel disease
Jong-Mi Lee, Joo Hee Jang, Ji Hyeong Ryu, Jaeeun Yoo, Bo-In Lee, Seung-Jun Kim, Eun-Jee Oh, Hsu-Heng Yen
PLOS ONE.2021; 16(8): e0255974. CrossRef
Endoscopy within 7 days after detecting high calprotectin levels can be useful for therapeutic decision-making in ulcerative colitis
Ho Min Yong, Sung-Jo Park, Seong Ran Jeon, Heesu Park, Hyun Gun Kim, Tae Hee Lee, Junseok Park, Jin-Oh Kim, Joon Seong Lee, Bong Min Ko, Hyeon Jeong Goong, Suyeon Park
Medicine.2021; 100(34): e27065. CrossRef
Development and Validation of a Test to Monitor Endoscopic Activity in Patients With Crohn’s Disease Based on Serum Levels of Proteins
Geert D’Haens, Orlaith Kelly, Robert Battat, Mark S. Silverberg, David Laharie, Edouard Louis, Edoardo Savarino, Giorgia Bodini, Andres Yarur, Brigid S. Boland, Waqqas Afif, Xiao-jun Li, Michael Hale, Jessica Ho, Venkateswarlu Kondragunta, Benjamin Huang,
Gastroenterology.2020; 158(3): 515. CrossRef
Faecal calprotectin in inflammatory bowel diseases: a review focused on meta-analyses and routine usage limitations
Emilio J. Laserna-Mendieta, Alfredo J. Lucendo
Clinical Chemistry and Laboratory Medicine (CCLM).2019; 57(9): 1295. CrossRef
Update on C-reactive protein and fecal calprotectin: are they accurate measures of disease activity in Crohn’s disease?
Christopher Ma, Robert Battat, Claire E. Parker, Reena Khanna, Vipul Jairath, Brian Gordon Feagan
Expert Review of Gastroenterology & Hepatology.2019; 13(4): 319. CrossRef
Approaches to Integrating Biomarkers Into Clinical Trials and Care Pathways as Targets for the Treatment of Inflammatory Bowel Diseases
Parambir S. Dulai, Laurent Peyrin-Biroulet, Silvio Danese, Bruce E. Sands, Axel Dignass, Dan Turner, Gerassimos Mantzaris, Juergen Schölmerich, Jean-Yves Mary, Walter Reinisch, William J. Sandborn
Gastroenterology.2019; 157(4): 1032. CrossRef
Faecal calprotectin to detect inflammatory bowel disease: a systematic review and exploratory meta-analysis of test accuracy
Karoline Freeman, Brian H Willis, Hannah Fraser, Sian Taylor-Phillips, Aileen Clarke
BMJ Open.2019; 9(3): e027428. CrossRef
Extraction, isolation, and concentration of calprotectin antigen (S100A8/S100A9) from granulocytes
Tom Nilsen, Siri Helen Haugen, Anders Larsson
Health Science Reports.2018;[Epub] CrossRef
Fecal Immunochemical Test and Fecal Calprotectin Measurement Are Noninvasive Monitoring Tools for Predicting Endoscopic Activity in Patients with Ulcerative Colitis
Ji Young Chang, Jae Hee Cheon
Gut and Liver.2018; 12(2): 117. CrossRef
Fecal calprotectin is not superior to serum C-reactive protein or the Harvey–Bradshaw index in predicting postoperative endoscopic recurrence in Crohn’s disease
Cristina Verdejo, Daniel Hervías, Óscar Roncero, Ángel Arias, Abdelmouneim Bouhmidi, Rufo Lorente, Irina Salueña, Alfredo J. Lucendo
European Journal of Gastroenterology & Hepatology.2018; 30(12): 1521. CrossRef
Experience of patients with inflammatory bowel disease in using a home fecal calprotectin test as an objective reported outcome for self-monitoring
Shu-Chen Wei, Chien-Chih Tung, Meng-Tzu Weng, Jau-Min Wong
Intestinal Research.2018; 16(4): 546. CrossRef
Serum Adipocytokine Levels as Surrogate Markers for Disease Activity of Crohn’s Disease
Su Hwan Kim, Seung Hyeon Jang, Ji Won Kim, Byeong Gwan Kim, Kook Lae Lee, You Sun Kim, Dong Soo Han, Joo Sung Kim
The American Journal of the Medical Sciences.2017; 353(5): 439. CrossRef
Fecal biomarkers in inflammatory bowel disease: how, when and why?
Paula Ministro, Diana Martins
Expert Review of Gastroenterology & Hepatology.2017; 11(4): 317. CrossRef
Could fecal calprotectin enter mainstream use for diagnosing and monitoring inflammatory bowel disease?
Shu Chen Wei
Intestinal Research.2016; 14(4): 293. CrossRef

8,082 View
76 Download
18 Web of Science
19 Crossref

Colitis Cystica Profunda Masquerading as a Pneumatosis Cystoides Intestinalis: A Case Report: Eun Suk Jung, Jae Hee Cheon, Kyong Joo Lee, Hyun Jung Lee, Hui Won Jang, Young Eun Chon, Kyu Sik Jung, Seonjung Chang, Sung Pil Hong, Tae Il Kim, Won Ho Kim; Intest Res 2010;8(2):187-190. Published online December 30, 2010; DOI: https://doi.org/10.5217/ir.2010.8.2.187

Abstract PDF: Colitis Cystica Profunda (CCP) is an uncommon and benign disease entity characterized by mucoid cysts located in the submucosal layer of the colon. It can mimic cystic submucosal tumors or mucinous adenocarcinoma and is usually located in the rectum. CCP is found in the ascending colon less frequently. CCP manifesting as multiple cystic tumors, similar to pneumatosis cystoides intestinalis, has not yet been reported. Recently, a case of CCP mimicking pneumatosis cystoides intestinalis in the ascending colon was treated. Here this case is reported and the literature reviewed. (Intest Res 2010;8:187-190)

2,597 View
30 Download

Clinical Experience of Thalidomide in the Treatment of Korean Patients with Intestinal BehcӇet's Disease: Pilot Experience in a Single Center: Hyun Jung Lee, Jae Hee Cheon, Kyong Joo Lee, Hui Won Jang, Kyu Sik Jung, Eun Suk Jung, Jin Ha Lee, Seung Min Jeon, Sung Pil Hong, Tae Il Kim, Won Ho Kim; Intest Res 2010;8(1):63-69. Published online June 30, 2010; DOI: https://doi.org/10.5217/ir.2010.8.1.63

Abstract PDF

Intestinal BehcӇet's disease (BD) often leads to severe complications, such as perforation or massive bleeding, and therefore is one of the major causes of morbidity and mortality. As thalidomide has been identified and its anti-inflammatory and immunomodulatory properties clarified, this drug has been used in cases of systemic BD with some success. Herein we report a case series of four patients with intestinal BD to share our clinical experience with thalidomide treatment. We studied the effects of thalidomide in four patients who had a chronic relapse of intestinal BD requiring the frequent use of systemic steroids due to refractoriness to prior treatments, such as 5-aminosalycylic acid and immunosuppressants. Pre- and post-treatment clinical and laboratory data, including clinical symptoms, laboratory data, disease activity index for intestinal BD, and thalidomide toxicity were recorded. Three of the four patients had a clinical and radiologic improvement after thalidomide treatment and all of the patients discontinued steroid therapy. Although two patients tolerated thalidomide, two patients could not continue the treatment because they suffered from edema and neutropenia. Thalidomide could be considered a therapeutic option for the treatment of intestinal BD. (Intest Res 2010;8:63-69)

Citations

Citations to this article as recorded by

Advances in Management of Intestinal Behçet’s Disease: A Perspective From Gastroenterologists
Jae Hee Cheon
Journal of Rheumatic Diseases.2021; 28(1): 4. CrossRef
An Overview of Conventional and Recent Treatment Options for Behcet’s Disease
Kader Cetin Gedik, Micol Romano, Roberta A. Berard, Erkan Demirkaya
Current Treatment Options in Rheumatology.2020; 6(2): 99. CrossRef
Updated treatment strategies for intestinal Behçet’s disease
Yong Eun Park, Jae Hee Cheon
The Korean Journal of Internal Medicine.2018; 33(1): 1. CrossRef
Update on the Medical Management of Gastrointestinal Behçet’s Disease
Giuseppe Lopalco, Donato Rigante, Vincenzo Venerito, Claudia Fabiani, Rossella Franceschini, Michele Barone, Giovanni Lapadula, Mauro Galeazzi, Bruno Frediani, Florenzo Iannone, Luca Cantarini
Mediators of Inflammation.2017; 2017: 1. CrossRef
An update on the diagnosis, treatment, and prognosis of intestinal Behçet's disease
Jae Hee Cheon, Won Ho Kim
Current Opinion in Rheumatology.2015; 27(1): 24. CrossRef
Update on the Treatment of Intestinal Behçet's Disease
Kyung-Jo Kim
Journal of Rheumatic Diseases.2014; 21(4): 176. CrossRef
The Medical Treatments of Intestinal Behçet's Disease: An Update
Hye Won Lee, Won Ho Kim, Jae Hee Cheon
Intestinal Research.2013; 11(3): 155. CrossRef
Efficacy of Infliximab in Intestinal Behçet’s Disease
Jin Ha Lee, Jae Hee Cheon, Seong Woo Jeon, Byong Duk Ye, Suk-Kyun Yang, Young-Ho Kim, Kang-Moon Lee, Jong Pil Im, Joo Sung Kim, Chang Kyun Lee, Hyo Jong Kim, Eun Young Kim, Kyeong Ok Kim, Byung Ik Jang, Won Ho Kim
Inflammatory Bowel Diseases.2013; : 1. CrossRef

3,107 View
30 Download
8 Crossref

Author index